FMP
Enanta Pharmaceuticals, Inc.
ENTA
NASDAQ
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
6.1 USD
-0.55 (-9.02%)
Historical Prices
From:
To:
About
ceo
Dr. Jay R. Luly Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.enanta.comexchange
NASDAQ
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
CIK
0001177648
ISIN
US29251M1062
CUSIP
29251M106
Address
500 Arsenal Street
Phone
617 607 0800
Country
US
Employee
131
IPO Date
Mar 21, 2013
Financial Statement
Earnings
ENTA Financial Summary
CIK
0001177648
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
29251M106
ISIN
US29251M1062
Country
US
Price
6.1
Beta
0.48
Volume Avg.
540.96k
Market Cap
130.13M
Shares
-
52-Week
4.71-17.8
DCF
-7.91
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.23
P/B
-
Website
https://www.enanta.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ENTA News
zacks.com
Feb 14, 2025
Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind...
Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
Feb 10, 2025
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue ...
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.58 per share a year ago.
businesswire.com
Feb 10, 2025
Enanta Pharmaceuticals Reports Financial Results for its Fis...
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal first quarter ended December 31, 2024. “2025 is primed to be a pivotal year for Enanta as we execute on multiple catalysts across our pipeline, including progression of our RSV compounds and expansion of our immunology portfolio. Recruitment for RSV.
businesswire.com
Dec 24, 2024
Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Pate...
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United States District Court of Massachusetts (“the Court”) has issued a ruling on a summary judgment motion filed by Pfizer, Inc. in connection with Enanta's patent infringement lawsuit seeking damages for infringement of U.S. Patent No. 11,358,953 (“the '953 Patent”) i.
zacks.com
Dec 23, 2024
Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This S...
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
businesswire.com
Dec 9, 2024
Enanta Pharmaceuticals Announces Positive Topline Results fr...
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced positive topline results from the first-in-pediatrics Phase 2 study evaluating zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months with respiratory syncytial virus (RSV). An antiviral effect was observed for the primary and secondary virology endpoi.
businesswire.com
Dec 6, 2024
Enanta Pharmaceuticals to Present Topline Results from First...
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the company will hold a conference call and webcast on Monday, December 9 at 8:30 a.m. ET to share topline results from RSVPEDs, a first-in-pediatrics Phase 2 study evaluating zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months with respiratory sync.
zacks.com
Nov 25, 2024
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenu...
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.36 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.33 per share a year ago.
